Primary Responsibilities：
Partnership Management and Cooperation：
1. Establish clear governance framework, communication mechanism and operation processes to ensure efficient and effective alliance with BD partners.
2. Manage a portfolio of partnerships, work closely with internal and external stakeholders to manage responsibilities, mitigate risks, and ensure alliance objectives are achieved.
3. Drive joint meetings (JSC, JDC, etc.) and communicate outcomes and insights for current and future assets; Provide strategic updates to governance team and senior management.
4. Identify, evaluate, and leverage scientific capabilities and technical platform of our partners to enhance the R&D capability of Henlius and rapidly expand the existing pipeline.
5. Timely and accurately report all financial elements in collaboration with finance and other teams.
Out Licensing Project Support
1. Support the assessment of market dynamics and future landscape to identify the licensing opportunities including early research projects, new modality platform, early and late clinical stage opportunities, and identify threats and risks in a timely manner.
2. Provide other support to out-licensing evaluation as required.
Contract Obligations
1. Identify and bring disputes and issues that may result in disputes (including without limitation any asserted occurrence of a material breach by a Party) to the attention of the JSC in a timely manner, and function as the point of first referral in all matters of conflict resolution.
2. Provide a single point of communication for seeking consensus both internally within the Parties’ respective organizations and between the Parties.
3. Plan and coordinate cooperative efforts, internal communications and external communications between the Parties with respect to this Agreement.
4. Take responsibility for ensuring that meetings and the issuance of meeting agendas and minutes occur as set forth in this Agreement, and that relevant action items resulting from such meetings are appropriately carried out or otherwise addressed.
5. Report the safety information of Henlius 's listed products (adverse events, other situations that can lead to adverse events, and unexpected treatment effects) within 24 hours after being informed.
